Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Pfizer (PFE)

NYSE: PFE · Pharmaceuticals · New York, NY

Our rating: Neutral

Neutral reaffirmed at $30.79, moderate conviction, November 4, 2026.

Breaks if: The Neutral call turns Positive if Pfizer's annual revenue returns to growth of 3% or more in the next 12-month reporting period, showing the base business has genuinely found its footing. It turns Cautious if revenue declines accelerate beyond 5% in the next two quarterly prints, or if free cash flow drops below $7B in the next annual filing — either would signal that the cash engine propping the current multiple is under real pressure, not just accounting noise.

Key figures

Market value$156.2B
Revenue, last 12 months$63.6B
Net income, last 12 months$4.0B
Free cash flow, last 12 months$11.8B
Price to earnings38.7×
Free cash flow yield7.5%
Dividend yield6.3%
Operating marginn/a
Return on equity4.4%
Beta to the S&P 5000.36
Volatility, annualized23.6%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 27, 2026$16.6B−0.4%$0.56$4.8B
June 28, 2026$15.0B2.6%$-0.04$302M
March 29, 2026$14.5B5.4%$0.47$2.2B
December 31, 2025$17.6B−1.2%$-0.29$4.5B
September 28, 2025$16.7B−5.9%$0.62$4.0B
June 29, 2025$14.7B10.3%$0.51−$1.2B
March 30, 2025$13.7B−7.8%$0.52$1.8B
December 31, 2024$17.8B21.9%$0.07$5.8B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

15 ledger entries and 16 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.